Education
About Us
Working with TipRanks
Follow Us
BioVie (BIVI)
NASDAQ:BIVI
BIVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.42 - $75.00
Previous CloseN/A
Volume1.62M
Average Volume (3M)456.94K
Market Cap
$14.01M
Enterprise Value$1.75M
Total Cash (Recent Filing)$17.54T
Total Debt (Recent Filing)$349.89B
Price to Earnings (P/E)―
Beta2.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding7,534,225
10 Day Avg. Volume350,486
30 Day Avg. Volume456,937
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$12.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BioVie News
BIVI FAQ
What was BioVie’s price range in the past 12 months?
BioVie lowest stock price was $1.42 and its highest was $75.00 in the past 12 months.
What is BioVie’s market cap?
BioVie’s market cap is $14.01M.
When is BioVie’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioVie’s earnings last quarter?
BioVie released its earnings results on Feb 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.055.
Is BioVie overvalued?
According to Wall Street analysts BioVie’s price is currently Undervalued.
Does BioVie pay dividends?
BioVie does not currently pay dividends.
What is BioVie’s EPS estimate?
BioVie’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVie have?
BioVie has 7,534,225 shares outstanding.
What happened to BioVie’s price movement after its last earnings report?
BioVie reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -0.761%.
Which hedge fund is a major shareholder of BioVie?
Among the largest hedge funds holding BioVie’s share is Sheaff Brock Investment Advisors LLC. It holds BioVie’s shares valued at 0.
BioVie Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (545.16% Upside)
$12.00 (545.16% Upside)
Hedge Fund Trend
Decreased
By 513.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.42%
12-Months-Change
Fundamentals
Return on Equity
-101.64%
Trailing 12-Months
Asset Growth
-14.46%
Trailing 12-Months
Company Description
BioVie
BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver disease, specifically targeting unmet medical needs in the treatment of chronic liver disorders and neurological conditions. The company's core products include NE3107, a novel molecule aimed at treating Alzheimer's and Parkinson's diseases, and BIV201, an innovative treatment for ascites due to liver cirrhosis.
BIVI Stock 12 Month Forecast
Average Price Target
$12.00
▲(545.16% Upside)
Technical Analysis
Ownership Overview
14.99% Insiders
1.21% Mutual Funds
0.39% Other Institutional Investors
83.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---